Lyu Wenliang, Cao Zhengmin, Ye Yong'an, Xing Lianjun
（ 100053） Department of Hepatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Jan 20;56(1):5-9. doi: 10.12182/20250160201.
Liver cirrhosis is the terminal stage of various acute and chronic liver diseases and ranks 11th among the most common causes of death worldwide. In recent years, with the progress of clinical research, there has been increasing support from evidence-based medicine for the treatment of liver cirrhosis with integrated traditional Chinese and Western medicine. In 2023, the Chinese Association of Integrative Medicine, the China Association of Chinese Medicine, and the Chinese Medical Association jointly released the first evidence-based guideline in this field, the . By combining the latest research at home and abroad, this article provides a detailed interpretation of the highlights in the guideline, including traditional Chinese medicine etiology and pathogenesis, diagnostic progress, disease and syndrome combination, stage-based diagnostic mode, and treatment strategies of integrated traditional Chinese and Western medicine. The aim is to enhance understanding of this guideline among health workers and promote the improvement of the diagnosis and treatment of liver cirrhosis with integrated traditional Chinese and Western medicine.
肝硬化是各种急慢性肝病的终末阶段，在全球最常见死因中位列第11位。近年来，随着临床研究的进展，中西医结合治疗肝硬化越来越得到循证医学的支持。2023年，中国中西医结合学会、中华中医药学会和中华医学会联合发布了该领域的首部循证指南——《肝硬化中西医结合诊疗指南》。本文结合国内外最新研究，对该指南中的亮点进行详细解读，包括中医病因病机、诊断进展、病证结合、分期诊断模式以及中西医结合治疗策略等。目的是增进卫生工作者对该指南的认识，促进中西医结合治疗肝硬化诊疗水平的提高。
